Fluidx Medical announces completion of trial enrollment for its novel embolic device, GPX. In this multi-center trial, GPX was used to treat a variety of primary and metastatic tumors, renal adenoma tumors, and a range of other arterial and venous applications.

GPX has shown promising results for tumor embolization and other uses where there is a desire for distal vessel bed penetration. Embolization is a procedure in which arterial or venous blood supply to an organ, malformation, aneurysm, bleed, tumor, and/or other abnormal area of issue is blocked. Interim results of the GPX study have been presented at recent annual congresses including Global Embolization Symposium & Technologies (GEST), Society of Interventional Radiology (SIR), and Leipzig Interventional Course (LINC).

Read more here